Drug interaction evaluation of the novel phosphodiesterase type 5 inhibitor tunodafil (youkenafil): Effects of tunodafil on omeprazole pharmacokinetics based on CYP2C19 gene polymorphism, and effects of ritonavir on tunodafil pharmacokinetics
Tunodafil slightly increased omeprazole exposure in the Extensive and Intermediate Metabolizers of CYP2C19, but had no significant effect on omeprazole exposure in the Poor Metabolizers. Ritonavir could strongly inhibit the metabolism of tunodafil, and the combination of tunodafil with ritonavir should be prohibited.
Authors
- Huan Zhou (ORCID: https://orcid.org/0000-0002-7316-8467)
- Juefang Ding
- Qinxin Song (ORCID: https://orcid.org/0000-0003-3452-6396)
- Xianjing Li (ORCID: https://orcid.org/0000-0002-0007-1429)
- Li Ding (ORCID: https://orcid.org/0000-0003-2813-0985)
- Keli Wang
- Juan Li (ORCID: https://orcid.org/0000-0002-2977-2966)
- Minlu Cheng
- Yuanxun Yang
Institutions
- China Pharmaceutical University (CN)
- Bengbu Medical College (CN)
- Nanjing Drum Tower Hospital (CN)
- First Affiliated Hospital of Bengbu Medical College (CN)
Publication Details
- Journal
- European Journal of Pharmaceutical Sciences
- Published
- 2025-01-09
- DOI
- https://doi.org/10.1016/j.ejps.2025.107010
- Citations
- 2
- Primary Topic
- Sexual function and dysfunction studies
- Type
- article
- Field-Weighted Citation Impact
- 2.94
Funders
- National Natural Science Foundation of China